This may be the most impressive and successful studies in cancer research. The study was conducted by the University of CA, San Diego and the Gerson Research Organization, title, “5-Year Survival Rates of Melanoma Patients treated by diet and therapy after the manner of Gerson.”
CONCLUSIONS: The 5-year survival rates reported here are considerably higher than those reported elsewhere. Stage IIIA/B males had exceptionally high survival rates compared with those reported by other centers.
RESULTS SUMMARIZED: Of 14 patients with stages I and II (localized) melanoma, 100% survived for 5 years, compared with 79%. Of 17 with stage IIIA (regionally metastasized) melanoma, 82% were alive at 5 years, in contrast to 39%. Of 33 with combined stages IIIA + IIIB (regionally metastasized) melanoma, 70% lived 5 years, compared with 41% of 134. Of 18 with stage IVA melanoma, 39% were alive at 5 years, compared with only 6%. Survival impact was not assessed for stage IVB.
This pilot study most likely has the world’s best results for any study ever conducted on pancreatic cancer.
RESULTS: As of 12 January 1999, of 11 patients entered into the study, 9 (81%) survived one year, 5 (45%) survived two years, and at this time, 4 have survived three years. Two patients are alive and doing well: one at three years and the other at four years.
CONCLUSION: These results are far above the 25% survival at one year and 10% survival at two years for all stages of pancreatic adenocarcinoma reported in the National Cancer Data Base from 1995.
Researchers at the University of Victoria in British Columbia did a careful follow up on 200 persons who underwent a “spontaneous regression of cancer”. They found that 87% of those persons had switched diets, usually to a vegetarian diet!!!
1-year survival rate among patients with pancreatic cancer was significantly higher among those who modified their diet than among those who did not (17 months versus 6 months). The one-year survival rate was 54.2 percent in the macrobiotic patients versus 10.0 percent in the controls. All comparisons were statistically significant. For patients with metastatic prostate cancer, a case control study demonstrated that those who ate macrobiotically lived longer (177 months compared to 91 months) and enjoyed an improved quality of life.
Want more information on chemotherapy specific to different types of cancer? This was a mega-study done by the Department of Radiation Oncology, Northern Sydney Cancer Centre…. RESULTS: The overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA. CONCLUSION: As the 5-year relative survival rate for cancer in Australia is now over 60%, it is clear that cytotoxic chemotherapy only makes a minor contribution to cancer survival. To justify the continued funding and availability of drugs used in cytotoxic chemotherapy, a rigorous evaluation of the cost-effectiveness and impact on quality of life is urgently required. – Full study attached.
Is this the future of chemotherapy? In 2003, the first clinical trial for cancer treatment with IPT was published in Uruguay. It showed improved clinical outcome for patients with advanced breast cancer. Also, in a another study In 2009, a Bulgarian three-year study showed that IPT improved patients’ quality of life. The researchers stated that they “sincerely believe that the method presents a compelling opportunity for solving the problem with chemotherapy’s toxicity, for improving treatment effectiveness and quality of life.” Note – IPT is NOT yet approved by the FDA. Attached is the Uruguay study.
Study by Jaakkola – RESULTS: From the time of diagnosis, at 6 months, the survival of the SEER (Conventional) group was 50% and the Nutrient group almost 95%; at 12 months, 20% of the SEER group and 85% of the Nutrient group was still alive; at 24 months, survival for the SEER group was only 10%, while 55% of the Nutrient group was still alive; at 30 months, only about 1% of the SEER group was still alive while 40% of the Nutrient group was still living, and ***finally at 6 years or 72 months, all of the SEER group had passed on, while 44% (8 of 18 patients) of the Nutrient group was still alive.***
“100 terminal cancer patients – After 10 days of intravenous Vitamin C therapy, each patient was given 10 grams of vitamin C orally each day indefinitely. RESULTS: The mean survival time for the ascorbate group (Vitamin C) was 4.2 TIME MORE than the control subjects (more than 210 days compared to 50 days for the controls). An analysis of the survival-time curves indicated that deaths occurred for about 90% of the ascorbate-treated patients at one-third the rate for the controls and that the other 10% had a much greater survival time, averaging more than 20 times the controls. CONCLUSION: Cameron and Pauling concluded that high doses of vitamin C should be given to all cancer patients.” The full study is on page 62 of the PDF.
“Dr. Thomas Rau, who runs the Paracelsus Clinic (cancer clinic since 1958) in Switzerland recently checked the records of the last 150 breast cancer patients treated in his clinic. He found that 147 of them (98%) had one or more root canal teeth on the same meridian as the original breast cancer tumor.” Attached is an article with more information on the subject:
A study of women with advanced breast cancer, conducted at Stanford University, found that those who attended weekly support groups lived an average of 18 months longer than those who didn’t.
"If your looking for someone that wants to help and find the cause of your sickness, Dr. Conners is the doctor for you."Vicki & Kiera Velna
"I finally have a plan and feel at peace with my cancer treatment decision. Thanks to Dr. Conners, I can now move forward with my life."Tamara Huss
"Dr. Conners gave me and my family peace of mind, hope and the ability to restore my health!"Randy & Beth Pratl